These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34080025)

  • 21. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
    Zhao H; Yang Q; Hu Y; Zhang J
    Oncol Rep; 2018 Dec; 40(6):3223-3234. PubMed ID: 30272286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.
    Zhang Z; Sun C; Zhang L; Chi X; Ji J; Gao X; Wang Y; Zhao Z; Liu L; Cao X; Yang Y; Mao W
    Biomed Pharmacother; 2019 Jan; 109():1541-1546. PubMed ID: 30551406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.
    Tang L; Wang M; Jiang L; Zeng C
    Hum Cell; 2020 Jul; 33(3):801-809. PubMed ID: 32388810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
    Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
    Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
    Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA
    Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.
    Wang W; Han D; Cai Q; Shen T; Dong B; Lewis MT; Wang R; Meng Y; Zhou W; Yi P; Creighton CJ; Moore DD; Yang F
    Nat Commun; 2022 Jan; 13(1):245. PubMed ID: 35017531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
    Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA.
    Liu Z; Mao S; Dai L; Huang R; Hu W; Yu C; Yang Y; Cao G; Huang X
    Bioorg Med Chem; 2024 Nov; 113():117936. PubMed ID: 39369565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
    Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
    Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Xie XF; Wu NQ; Wu JF; Zhang GL; Guo JF; Chen XL; Du CW
    Cancer Lett; 2022 Dec; 551():215944. PubMed ID: 36209974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
    Wang SP; Wu SQ; Huang SH; Tang YX; Meng LQ; Liu F; Zhu QH; Xu YG
    Cell Death Dis; 2021 Dec; 12(12):1138. PubMed ID: 34880209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.